100 related articles for article (PubMed ID: 9532378)
1. [Treatment of the endometrial adenomatosis with tamoxifen in patients of reproductive age].
Smetnik VP; Chernukha GE; Kushlinskiĭ NE
Biull Eksp Biol Med; 1998 Jan; 125(1):93-7. PubMed ID: 9532378
[No Abstract] [Full Text] [Related]
2. [The realization of the antiestrogen effect of tamoxifen in endometrial adenomatosis in women of reproductive age].
Putyrskaia NP; Chernukha GE
Akush Ginekol (Mosk); 1993; (6):43-6. PubMed ID: 8311158
[TBL] [Abstract][Full Text] [Related]
3. [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
Hauth E; Libera H; Kimmig R; Forsting M
Rofo; 2006 Mar; 178(3):316-23. PubMed ID: 16508840
[TBL] [Abstract][Full Text] [Related]
4. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
5. [Precancerous lesion of the endometrium and endometrial morphology in patients with tamoxifen therapy].
Schmidt D; Horn LC
Zentralbl Gynakol; 2002 Jan; 124(1):3-9. PubMed ID: 11873307
[TBL] [Abstract][Full Text] [Related]
6. Endometrial cancer: current concepts and management.
Ball HG; Elkadry EA
Surg Oncol Clin N Am; 1998 Apr; 7(2):271-84. PubMed ID: 9537976
[TBL] [Abstract][Full Text] [Related]
7. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
8. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
9. Changes in the endometrium caused by endogenous hormonal dysfunction.
Dallenbach-Hellweg G
Verh Dtsch Ges Pathol; 1997; 81():213-8. PubMed ID: 9474872
[TBL] [Abstract][Full Text] [Related]
10. [Nucleolar organizers and mitotic conditions in endometrial hyperplasia and carcinomaĭ].
Ellinidi VN; Pozharisskii KM
Vopr Onkol; 1999; 45(6):636-40. PubMed ID: 10703512
[TBL] [Abstract][Full Text] [Related]
11. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
12. Hyperglycemia secondary to megestrol acetate for endometrial neoplasia.
Rose PG
Gynecol Oncol; 1996 Apr; 61(1):139-41. PubMed ID: 8626102
[TBL] [Abstract][Full Text] [Related]
13. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
14. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
15. Function of insulin-like growth factor (IGF-I) and its binding protein (IGFBP-1) in pathological proliferation of endometrium.
Waksmański B; Dudkiewicz J; Dabrowski S
Wiad Lek; 2001; 54(11-12):656-61. PubMed ID: 11928553
[TBL] [Abstract][Full Text] [Related]
16. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR
Hum Reprod; 2006 Feb; 21(2):545-53. PubMed ID: 16210385
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology.
Kennedy MM; Baigrie CF; Manek S
Int J Gynecol Pathol; 1999 Apr; 18(2):130-7. PubMed ID: 10202670
[TBL] [Abstract][Full Text] [Related]
18. [Estrogen-progesterone therapy in glandular cystic hyperplasia and adenomatosis of the endometrium].
Hernandez Pineda P; Reyes Ceja L; Karchmer S; Valenzuela S; Zarate A
Ginecol Obstet Mex; 1968 Jun; 23(140):707-17. PubMed ID: 5739481
[No Abstract] [Full Text] [Related]
19. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update.
Horn LC; Meinel A; Handzel R; Einenkel J
Ann Diagn Pathol; 2007 Aug; 11(4):297-311. PubMed ID: 17630117
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and endometrial pathologies: a prospective study.
Seoud M; Shamseddine A; Khalil A; Salem Z; Saghir N; Bikhazi K; Bitar N; Azar G; Kaspar H
Gynecol Oncol; 1999 Oct; 75(1):15-9. PubMed ID: 10502419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
